Skip to main content
. 2021 Jul 7;2(3):100654. doi: 10.1016/j.xpro.2021.100654

Figure 6.

Figure 6

Quantification of GFAP-immunoreactive areas in the cerebral cortex

(A and A′) Representative images of GFAP immunoreactivity in the neocortex. The neocortex is outlined by a red line (A). The red marked areas in (A′) indicate the GFAP-immunoreactive area in the neocortex.

(B and B′) Higher power views of GFAP immunoreactivity in the neocortex. Highlighted magenta areas in (B′) indicate the GFAP-immunoreactive area.

(C and C′) Representative images of GFAP immunoreactivity in the hippocampus. The hippocampus is outlined by a red line (C). The red marked areas in (C′) indicate the GFAP-immunoreactive area in the hippocampus.

(D and D′) Higher power views of GFAP immunoreactivity in the hippocampus. Highlighted magenta areas in (D′) indicate the GFAP-immunoreactive area.

Scale bar: 100 μm.